WASHINGTON — Federal health advisers say AstraZeneca's Onglyza and a related diabetes drug should carry new information about a possible association with heart failure and death.
The Food and Drug Administration's panel of diabetes experts voiced concern about data suggesting Onglyza and Kombiglyze can increase hospitalization due to heart failure and overall mortality. The panel voted 14-1 that that information should appear on the drugs' prescribing labeling. Yet the panel...
07:05 Half of Scots don't want independence vote before Brexit: YouGov poll18
03:32 Asia stocks rise, euro steady as relief from French vote buoys sentiment22
15:08 Euro surges, yen dives as French election fears abate24
12:22 French election result gives markets a start-of-week lift26